Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices

During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.

Alex Azar, Trump’s HHS secretary nominee, who spoke at the Senate HELP committee 11/29/17 — • Source: Ferdous Al-Faruque

Alex Azar's drug pricing agenda should he become Health and Human Services Secretary includes ensuring clearer times for generic entry, as well as removing barriers posed by Risk Evaluation and Mitigation Strategies (REMS).

During a hearing Nov. 29 on his nomination in front of the Senate Health, Education, Labor and Pensions Committee, Azar...